Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers–current evidence and future directions
RCT Lam, D Johnson, G Lam, MLY Li… - Frontiers in …, 2022 - frontiersin.org
Advances in Next Generation Sequencing (NGS) technologies have enabled the accurate
detection and quantification of circulating tumor-derived (ct) DNA in most gastrointestinal …
detection and quantification of circulating tumor-derived (ct) DNA in most gastrointestinal …
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
B Doleschal, A Petzer, H Rumpold - Frontiers in Oncology, 2022 - frontiersin.org
Anti-EGFR targeting is one of the key strategies in the treatment of metastatic colorectal
cancer (mCRC). For almost two decades oncologists have struggled to implement EGFR …
cancer (mCRC). For almost two decades oncologists have struggled to implement EGFR …
[HTML][HTML] Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors
EL Verner, JB Jackson, E Severson… - The Journal of Molecular …, 2023 - Elsevier
Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid
biopsy testing is a complementary approach to tissue testing, particularly when tissue is not …
biopsy testing is a complementary approach to tissue testing, particularly when tissue is not …
Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors–can we RECIST? Focus on colorectal cancer
KLG Spindler, A Jakobsen - Therapeutic Advances in …, 2023 - journals.sagepub.com
Interest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC)
has increased during the past decade. The analysis of quantitative ctDNA changes as a …
has increased during the past decade. The analysis of quantitative ctDNA changes as a …
[HTML][HTML] Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer
G Valenzuela, M Burotto, K Marcelain… - World Journal of …, 2022 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is a major cause of mortality worldwide, associated with a steadily
growing prevalence. Notably, the identification of KRAS, NRAS, and BRAF mutations has …
growing prevalence. Notably, the identification of KRAS, NRAS, and BRAF mutations has …
Next-generation sequencing of circulating tumor DNA can optimize second-line treatment in RAS wild-type metastatic colorectal cancer after progression on anti …
D Mauri, K Kamposioras, D Matthaios, M Tolia… - Oncology research and …, 2022 - karger.com
Background: Management of Ras wild-type colorectal cancer (CRC) patients upon disease
progression after the successful use of targeted treatment with anti-EGFR monoclonal …
progression after the successful use of targeted treatment with anti-EGFR monoclonal …
Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling
Simple Summary Patients with atypical (nonV600) BRAF mutations represent a unique
category of metastatic colorectal cancer patients. In the past, these patients were considered …
category of metastatic colorectal cancer patients. In the past, these patients were considered …
[PDF][PDF] Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors
C Maddox, PM McGregor III, A Karandikar, SB Hastings… - 2023 - oncology.labcorp.com
Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid
biopsy testing is a complementary approach to tissue testing, particularly when tissue is not …
biopsy testing is a complementary approach to tissue testing, particularly when tissue is not …